Compounded tirzepatide costs $85.58 to $399 a month

Every way to pay for compounded tirzepatide

The same molecule, three ways to buy it. Manufacturer prices are its own published self-pay list and carry no link; program prices are all in, membership included, read off each seller’s own page.

How to choose a compounded tirzepatide program: 7 checks

Price ranks the list. These decide whether the cheapest is cheapest for you. Each count is from the programs on this page, today.

The price at your dose

2 of 2 hold one price at every dose

Advertised prices are usually the starting dose. A seller that charges more as you step up can end up dearer than one with a higher entry price.

How long you commit

14 of 14 sell compounded tirzepatide month to month

13 of 14 publish cancel-anytime terms. A low price that needs a 6 or 12-month prepay is a loan to the seller if you stop early.

Fees on top

1 of 14 add a membership fee

None charge a separate consultation. We rank on the all-in price so a fee cannot hide.

Insurance

2 of 14 take insurance

Most cash programs cannot bill your plan. If your plan covers a brand GLP-1, a copay can beat every cash price here.

Brand or compounded

5 of 14 also sell an FDA-approved brand

Compounded versions are cheaper and not FDA-approved. If you want the approved drug later, a seller that stocks both saves a switch.

Who stands behind it

1 of 14 carry a LegitScript certificate we confirmed

A real program names its clinician network and its pharmacy. LegitScript certifies telehealth sellers; check a certificate on legitscript.com, not on a badge the seller hosts.

Where you live

5 of 14 ship to all 50 states

State rules decide who can prescribe and dispense. Check your state before you pay an intake fee.

Red flags: walk away if

• ×The box arrives warm or with too little ice. FDA says do not use it.^[2]
• ×The seller will not name the pharmacy, or the one on the label is not on your state board's register.^[2]
• ×Nobody assesses you before the sale. Compounded drugs are for patients a clinician has assessed.^[2]
• ×Your dose comes in mg with no syringe units, or above the dose on the brand's label.^[2] Convert mg to units
• ×You are told to keep using a vial more than 28 days after first opening it.^[2]

Why trust this page

• PricesRead from each seller’s own page and dated, weekly. 149 recorded checks across 14 sellers since August 2026. How we verify
• OrderPrice only, all in. We earn a commission from some programs and it never moves a row. How we make money
• Written byJulian Caraulani, Founder, PriceTracker GLP-1.
• Clinical reviewDr. A. Goher, MD reviews the clinical statements only, never prices, rankings or which programs pay us.

We track prices. Every clinical and manufacturer claim about Compounded tirzepatide on this page is quoted below in its source’s own words, with the date we read it. We do not write medical guidance and we do not tell anyone what dose to take.

Guides on Compounded tirzepatide

• Compounded tirzepatide in 2026Buying safely
• Generic Tirzepatide (2026)What it costs
• Tirzepatide Cost 2026What it costs

References

1. Eli Lilly, Zepbound cost information, read October 2026

   The list price of Zepbound is $499 - $1,086.37 per fill, but the amount you pay will largely depend on your prescription drug insurance plan. ... Available through Zepbound self-pay, Zepbound is offered as a 4‑count single‑dose vial (0.5mL) and a single‑patient‑use KwikPen (2.4mL, 0.6mL/dose) in doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, with direct‑to‑patient pricing of $299, $399, $499, $699, $699 and $699 respectively. ... If you have commercial drug insurance with coverage for Zepbound, you may be eligible to pay as low as $25 for a one- or three-month supply Zepbound single-dose pens.

2. FDA, concerns with unapproved GLP-1 drugs used for weight loss, read October 2026

   FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist. In other cases, the labels ... contain the name of a licensed pharmacy that, based on information FDA has gathered, did not compound these products. ... FDA has received complaints that certain compounded GLP-1 drugs have arrived warm or with inadequate ice packs ... The agency recommends patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, as this can affect the drug’s quality. ... Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days.

3. IRS Publication 502, Medical and Dental Expenses (Medicines; Weight-Loss Program), read October 2026

   You can include in medical expenses amounts you pay for prescribed medicines and drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual. ... You can include in medical expenses amounts you pay to lose weight if it is a treatment for a specific disease diagnosed by a physician (such as obesity, hypertension, or heart disease).

4. IRS Publication 969, Health Savings Accounts and Other Tax-Favored Health Plans, read October 2026

   In general, “qualified medical expenses” means amounts paid by the HSA beneficiary for “medical care” (as defined in Code section 213(d)) ... but only to the extent the amounts are not compensated for by insurance or otherwise. ... Qualified medical expenses are those specified in the plan that would generally qualify for the medical and dental expenses deduction.

5. FDA, compounder policy update on GLP-1 supply, read October 2026

   Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list. ... For a state-licensed pharmacy or physician compounding, dispensing or distributing semaglutide injection products under section 503A of the FD&C Act, the period of enforcement discretion (described below) has ended.

6. FDA, proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, read October 2026

   The U.S. Food and Drug Administration today announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. ... “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary, M.D., M.P.H. ... The FDA is now inviting interested parties to submit comments electronically through the docket by June 29, 2026.

7. American College of Cardiology on SURMOUNT-5 (tirzepatide vs semaglutide, head to head), read October 2026

   at 72 weeks, the least-squares mean percent change in body weight was −20.2% for tirzepatide users vs. −13.7% for semaglutide users (p<0.001)